Merck and Neuromed ax drug development progra

Guest Contributor
September 19, 2007

Merck Frosst & Co and Vancouver-based Neuromed Pharmaceuticals have discontinued their collaboration on NMED-160, a Phase II compound for the treatment of chronic pain. The companies concluded that the compound did not have "the ideal pharmaceutical characteristics considered necessary to advance the compound further". The two firms will continue their research collaboration evaluating alternate, earlier stage drug candidates. Neuromed says the collaboration with Merck resulted in the discovery of additional N-type calcium channel blockers for pain that are moving towards clinical trials....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.